Who are ABT-494's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leqselvi, Cibinqo, Cibinqo, ABROCITINIB, Jyseleca, Abrocitinib 100 mg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abt-494.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ABT-494 — Competitive Intelligence Brief

ABT-494 (ABT-494) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK1 inhibitor. Area: Immunology.

phase 2 JAK1 inhibitor JAK1 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ABT-494 (ABT-494) — AbbVie. ABT-494 is a JAK1 inhibitor that selectively blocks Janus kinase 1 signaling to reduce inflammatory cytokine production and immune cell activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABT-494 TARGET	ABT-494	AbbVie	phase 2	JAK1 inhibitor	JAK1
Leqselvi	DEURUXOLITINIB	Sun Pharm Inds Inc	marketed		JAK1, JAK2, TYK2	2024-01-01
Cibinqo	abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
Cibinqo	Abrocitinib	Pfizer	marketed	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK1	2022-01-01
ABROCITINIB	ABROCITINIB		marketed	Janus Kinase Inhibitor [EPC]	JAK1	2021-01-01
Jyseleca	FILGOTINIB	Gilead Sciences Ireland UC	marketed		Tyrosine-protein kinase JAK1	2020-01-01
Abrocitinib 100 mg	abrocitinib-100-mg	Pfizer	marketed	Janus kinase inhibitor	JAK1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK1 inhibitor class)

AbbVie · 2 drugs in this class
Arcutis Biotherapeutics, Inc. · 1 drug in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-494 — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-494. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab